Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Summary

This randomized controled open label clinical trial conducted in patients with hypoxemic respiratory failure admitted to the ICU and requiring ventilatory support (invasive or non-invasive) is to evaluate whether treatment with cyproheptadine, a serotonin receptor antagonist, compared to usual care, increases the number of ventilator-free days.

Timeline

Start

2021-07-26

Primary completion

2022-01-26

Completion

2022-02-28

Drugs

Indications